Detalhe da pesquisa
1.
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Hepatology
; 73(2): 625-643, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33169409
2.
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Am J Gastroenterol
; 116(9): 1896-1904, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465693
3.
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
J Hepatol
; 70(1): 133-141, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30291868
4.
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Gastroenterology
; 155(4): 1140-1153, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29990488
5.
Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
Am J Gastroenterol
; 113(6): 863-871, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695828
6.
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
N Engl J Med
; 370(16): 1483-93, 2014 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24725238
7.
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
N Engl J Med
; 370(20): 1879-88, 2014 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24720702
8.
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).
Hepatology
; 64(2): 360-9, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26704148
9.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1075-86, 2015 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467591
10.
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Hepatology
; 61(4): 1127-35, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25614962
11.
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
Ann Hepatol
; 15(6): 834-845, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27740516
12.
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
Ann Intern Med
; 163(1): 1-13, 2015 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25909356
13.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
Lancet
; 384(9956): 1756-65, 2014 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25078309
14.
Preliminary study of two antiviral agents for hepatitis C genotype 1.
N Engl J Med
; 366(3): 216-24, 2012 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22256805
15.
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
J Hepatol
; 61(6): 1238-46, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25064437
16.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
N Engl J Med
; 361(6): 580-93, 2009 Aug 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-19625712
17.
Racial differences in hepatitis C treatment eligibility.
Hepatology
; 54(1): 70-8, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21488082
18.
Peginterferon-α-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation.
J Clin Gastroenterol
; 46(8): 700-8, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22739223
19.
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
Gastroenterology
; 139(1): 120-9.e18, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20399780
20.
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Hepatology
; 49(6): 1838-46, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19291790